Results 201 to 210 of about 35,587 (246)
Supplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Annette S. Kim, Steve L. McAfee, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Dylan M. Marchione, Vincent T. Ho, Yi‐Bin Chen +11 moreopenalex +1 more sourceDiagnostic and predictive molecular biomarkers in brain tumors across the lifespan: an age-stratified consensus statement. [PDF]
J NeurooncolMastronuzzi A, Franceschi E, D'Antonio F, Bennicelli E, Berzero G, Cella E, Filippi M, Lanzetta G, Marchioni E, Milanaccio C, Simonelli M, Bini P, Silvani A, Pace A. +13 moreeuropepmc +1 more sourceProteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells. [PDF]
Int J Mol SciRavn Berg S, Brambilla A, Hagen L, Sharma A, Vågbø CB, Liabakk NB, Kissova M, Arano Barenys M, Bjørås M, Torp SH, Slupphaug G. +10 moreeuropepmc +1 more sourceFigure S3 from D-2-HG Inhibits <i>IDH1<sup>mut</sup></i> Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation [PDF]
Sean T. Pianka, Tie Li, Terry J. Prins, Blaine S.C. Eldred, Bryan M. Kevan, Haowen Liang, Serendipity Zapanta Rinonos, Harley I. Kornblum, David A. Nathanson, Matteo Pellegrini, Linda M. Liau, Phioanh L. Nghiemphu, Timothy F. Cloughesy, Albert Lai +13 moreopenalex +1 more sourceOutcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. [PDF]
LeukemiaCroden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. +27 moreeuropepmc +1 more source